OR WAIT null SECS
July 13, 2022
Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.
July 12, 2022
Wacker is investing more than €100 million (US$100.5 million) to expand its Halle, Germany, site with an mRNA competence center.
July 08, 2022
Coya Therapeutics has secured intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids.
VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.
NRG Therapeutics and Domainex aim to develop novel small-molecule drugs to treat neurodegenerative disorders, such as Parkinson’s disease.
LG Chem has decided to proceed with IND-enabling studies and has renewed a license with Avacta.
July 02, 2022
As a result of the disruptions caused by the COVID-19 pandemic, global arbitration has adapted to a ‘new normal’.
Pharma should expand on successful cell therapies in oncology by applying these development and manufacturing methods to neuronal cell therapies.
June 30, 2022
Ipsen will acquire Epizyme, who recently had their lead medicine Tazverik (tazemetostat) approved by FDA for treatment of relapsed or refractory follicular lymphoma.
June 27, 2022
ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.